The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports
Novel Drug Reduces COVID-19 Deaths by 55% in Ph. 3 Trial
Shares of Veru Inc. traded 180% higher after company reported interim data from a Phase 3 clinical study of its COVID-19 drug candidate sabizabulin which was shown to reduce deaths in hospitalized patients by 55%.Co. Uses Protein Modulation to Treat Cancer
Nurix Therapeutics Inc. shares traded 13% higher after the company reported Q1/22 financial results and released an outline for two poster presentations that will be submitted at the American Association for Cancer Research Annual Meeting this weekend.FDA Approves Bipolar and Schizophrenia Drug
BioXcel Therapeutics Inc. reported that the U.S. FDA has approved its IGALMI™ (dexmedetomidine) Sublingual Film for use in acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.Can We Make a Pill to End the Pandemic?
Contributed Opinion
Vision and Value discusses the state of the virus and big pharma's race to slow the death rate as well as the spread of the pandemic — and what it means for investors.
Biopharma Co. Begins Dosing in Ph. 1 Solid Tumor Trial
NGM Biopharmaceuticals Inc. shares rose 14.75% after the company reported it dosed the first group of patients in its Phase 1/1b clinical trial of NGM831 for use in treating advanced solid tumors.Chen's Top Picks for Q2 2022
Asset manager and contributing writer Chen Lin looks to the biotechnology and mining sectors for his top second quarter picks.Biotech Co. Posts Notable PFS Gains in Ph. 3 Cancer Trial
Clovis Oncology Inc. shares traded 36% higher after the company reported that in the Phase 3 ATHENA-MONO clinical study its Rubraca® (Rucaparib) was shown to significantly improve progression-free survival in women diagnosed with ovarian cancer.Biotech Firm's Shares Double on $6B Deal
Shares of IGM Biosciences Inc. traded 97% higher after the company reported FY/21 financial results and announced it entered into a collaborative partnership with Sanofi SA to develop six separate IgM antibody agonists for three oncology and three autoimmune/inflammation targets.Biotech Co. Posts Positive Data in Ph. 1/2 Kidney Cancer Trial
Shares of 4D Pharma Plc. traded 28% higher after the company reported positive interim results from its Phase 1/2 study of its MRx0518 in combination with Merck & Co.'s KEYTRUDA® (pembrolizumab) for use in treating renal cell carcinoma.Biotech Co. Gets $2M Grant for Parkinson's Treatment
Shares of SQZ Biotechnologies Co. traded 17% higher after the company reported that it has been awarded a $2 million grant from the NIH to develop a new cell replacement therapy for use in treating Parkinson's disease.Co. Awaits FDA Approval of Drug, Prepares for Launch
Research Report
The biopharma's executive team is managing both time and opex spending well, noted an Oppenheimer report.
Drug Co. Gets PDUFA Date for TKI
Research Report
"We expect poziotinib approval in late 2022 with sales of $21.9 million this year," noted an H.C. Wainwright & Co. report.
Pharma Co. Gains FDA Approval for Epilepsy Seizure Drug
Shares of Marinus Pharmaceuticals Inc. jumped 16.4% higher near the end of trading today after the company reported that the U.S. FDA granted approval for its ZTALMY® (ganaxolone) in treating a rare type of genetic epilepsy called CDKL5 deficiency disorder.Catalyst Could Push Pharma to Break Out
Contributed Opinion
This pharmaceutical company is trading well below its cash value and is on the cusp of a potentially significant catalyst, one analyst says.
Biopharma Co. Enjoys Gains From Kidney Cancer Drug
Shares of this pharmaceuticals co. traded 22% higher after the company reported Q4/21 and FY/21 financial results that included a 17% sequential gain in net revenue from sales of its FOTIVDA® (tivozanib), which has been approved by the U.S. FDA for treating adults with relapsed or refractory advanced renal cell carcinoma (RCC).License Revenues Kick in for Biopharma Co.
Shares of Clearside Biomedical Inc. traded 42% higher after the company reported Q4/21 and FY/21 financial results and provided an update regarding positive developments at the company including the receipt of over $20 million in milestone payments from its commercial development partner.Biotech Firm Should Increase Sales by 20% This Year
Research Report
This immunotherapy company's outlook for 2022 is positive with expected growth in overall product sales and progress on the clinical front, noted an H.C. Wainwright & Co. report.
Co.'s Catalyst Rich 2022 Includes NDA, MAA Filings
Research Report
An Oppenheimer report notes that this pharmaceutical company is working to expand the approved uses of its lead drug candidate, and numerous catalysts involving Empaveli are expected this year.
Pharma Co. Shares Get a Bang from FDA Orphan Drug Approval
Shares of C4 Therapeutics Inc. traded 16% higher after the biopharma company reported that the U.S. FDA granted Orphan Drug approval status for its CFT8634 for use in treating soft tissue sarcoma.This Year Should Be Catalyst Rich for Oncology Pharma Co.
Research Report
An outperform-rated biopharma, which has a robust year of significant events ahead, is trading now at a significant discount, noted a Wedbush report.